The FDA won't care that CYP stuffed up MEND. They'll care about the trial designs of the trials that relate to their own approvals and be too busy for silliness that doesn't.
But shareholders should. I do. And I think prospective partners thinking about working with us would.
@truss20 - I don't believe you ever commented on whether you accept my criticism that failing to account for prone positioning in ARDS as part of the standard of care specification was a design flaw or not. I would be interested in what you think.
I still think it was. But I wouldn't have known that prone positioning made a difference (was a potential confounding variable) if I hadn't done some reading about ARDs - which I probably only did because I had an interest in the trial- its something that could have been overlooked. But I don't think a very good trial designer would have overlooked it.
One of pfiefer's recent posts references a youngish Aussie researcher that was at one stage named in the trial protocol as a contact. Cerebral Palsy Foundation or something I think.
I did read that post and check out links and think about the possibility of CYP cells being used for a trial. The Cerebral Palsy foundation (not sure of the name probably Alliance) had been trying to get a phase 3 done with umbilical chord stem cells (getting sufficient cells being the problem at phase 3). They'd also been trying to get something done in Holland regarding stroke. So if they look at CYP cells for stroke we won't be the first place they've looked. My general impression was that they were struggling to get resources and so had gone just about everywhere and that stem cells aren't a great match - they do do some good, do improve patients quality of life, but not heaps - but being a patient funded group they are really struggling but they - the associated researchers (I do accept Australia has a good proportion of the worlds best here) have to keep trying to keep hope alive for the patient group that is providing the funding. I'll tag you here @pfeifer1982 so you see I checked out your post - but don't reply unless your interested. And if you want you can cut an paste from here back to your own as I'm replying to pledge here.
- Forums
- ASX - By Stock
- CYP
- Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure, page-184
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $35.20M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.5¢ | $1.705K | 8.654K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 12792 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 32500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 12792 | 0.195 |
4 | 126276 | 0.190 |
4 | 17855 | 0.180 |
2 | 5997 | 0.175 |
1 | 50000 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 32500 | 1 |
0.205 | 46000 | 1 |
0.210 | 60000 | 1 |
0.220 | 1875 | 1 |
0.240 | 10000 | 1 |
Last trade - 10.02am 30/08/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online